Decorative Border

Innovations in Neurocritical Care

We aspire to be the total solutions company providing innovation in neuroinformatics and interventions to improve outcomes and efficiencies across the continuum of care for neurocritical care patients. Our portfolio is built on an expert understanding of desired outcomes and intense focus on unmet needs of neurocritical care.

Neurapheresis™ Cerebrospinal Fluid (CSF) Treatment Platform

Our mission for the Neurapheresis CSF Treatment Platform is to develop a safe, device-based alternative for treating debilitating and life-threatening diseases that involve foreign bodies in the cerebrospinal fluid.

Neurapheresis Therapy

Our CSF Treatment Platform offers a tailored process for the treatment and return of cerebrospinal fluid, called Neurapheresis Therapy.

Our first in-human application for Neurapheresis Therapy is in post-aneurysmal subarachnoid hemorrhage (aSAH) patients where it is intended to rapidly remove red blood cells from the CSF shortly after aSAH securement.

It is theorized that early, rapid filtration of red blood cells and their released cytotoxic byproducts post-SAH may contribute to a shorter length of stay, less utilization of hospital resources, improved clinical functional outcomes, and an overall reduced healthcare economic burden.1

PILLAR, the first clinical trial using Neurapheresis in subarachnoid hemorrhage patients was successfully completed. Results are in press.

What is Aneurysmal Subarachnoid Hemorrhage?

Aneurysmal subarachnoid hemorrhage (aSAH) is a serious, life-threatening event caused by a ruptured aneurysm (bleeding into the space surrounding the brain). Treatment focuses on stopping the bleeding, restoring normal blood flow, relieving the pressure on the brain, and preventing secondary injury due to neuro-inflammation as the body reabsorbs blood from the subarachnoid space.

Neurapheresis Collaboration and Research

To further our mission to develop a safe, device-based alternative for treating debilitating and life-threatening diseases that involve foreign bodies in the cerebrospinal fluid, we have created the Neurapheresis Research Consortium (NRC). For more information on initiatives for Neurapheresis Therapy beyond aSAH, please visit https://www.neurapheresis.org.

CAUTION-Investigational device. Limited by Federal (or United States) law to investigational use.

1 Bardutzky J et al. EARLYDRAIN- Outcome after Early Lumbar CSF-Drainage in Aneurysmal Subarachnoid
Hemorrhage: Study Protocol for a Randomized Controlled Trial. Trials 12 (2011):203.
2 US Brain Aneurysm Foundation,https://www.bafound.org/aneurysm-complications.
3 Lindegaard K et al. Clinical course of spontaneous subarachnoid hemorrhage: a population based study in Kind County, Washington. Neurology. 1993 Apr;43(4):712-8.